| 04/28/2026 2:38 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/06/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/03/2026 8:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 3:25 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/01/2026 3:26 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:16 PM | Mandil-Levin Revital (2125058) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 7:49 AM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/30/2026 7:51 AM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
Get the Latest News and Ratings for NRSNW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 03/24/2026 9:11 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 2:35 PM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Leuchtenberger Mark (1303315) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Golan Roy (1999257) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | Claiborne Cary J (1370930) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | NeuroSense Therapeutics (1875091) Issuer Tracik Ferenc (2120172) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 11:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/11/2026 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/18/2026 8:21 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 4:28 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 01/06/2026 4:27 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 10:49 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/08/2025 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 7:39 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B3 | |
| 11/25/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 11/21/2025 5:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 3:26 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 10/06/2025 8:06 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/25/2025 8:23 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 1:35 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 7:59 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 8:01 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/02/2025 7:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/21/2025 3:56 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/20/2025 8:31 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/18/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 08/18/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 08/08/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B5 | |
$30 stock to buy before Starlink goes public (WATCH NOW!) (Ad) A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker. Watch the free video to get the ticker today. |
| 08/01/2025 8:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/10/2025 8:21 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/26/2025 8:15 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |